ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0093

Disparities in CKD Risks: Data from the CURE-CKD COVID-19 Sub-Registry

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Nicholas, Susanne B., University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, United States
  • Follett, Robert W., University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, United States
  • Tacorda, Theona T., University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, United States
  • Wang, Xiaoyan, University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, United States
  • Ruenger, Dennis, University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, United States
  • Petousis, Panayiotis, University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, United States
  • Zhu, Bing, University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, United States
  • Davis, Tyler Austin, University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, United States
  • Zamanzadeh, Davina J., University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, United States
  • Daratha, Kenn B., Providence St Joseph Health, Spokane, Washington, United States
  • Jones, Cami R., Providence St Joseph Health, Spokane, Washington, United States
  • Norris, Keith C., University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, United States
  • Tuttle, Katherine R., Providence St Joseph Health, Spokane, Washington, United States
  • Bui, Alex, University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, United States

Group or Team Name

  • CURE-CKD
Background

The SARS-CoV-2 pandemic accelerated health disparities in chronic kidney disease (CKD). Here, we describe risk factors and access to care surrogates (area deprivation index-ADI) for clinical outcomes among SARS-CoV-2-tested patients in the CURE-CKD Registry.

Methods

We formed a COVID-19 Sub-Registry within CURE-CKD (1/1-6/30/2021; N=171,988) of patients with CKD, diabetes (DM)/pre-DM, or hypertension (HTN) with SARS-CoV-2 testing at UCLA Health (UCLA; N=17,884) and Providence St. Joseph Health (PSJH; N=154,104). Statistical analyses and fitted multivariable logistic regression models were adjusted for age and sex. The UCLA cohort included analyses for acute kidney injury (AKI), ADI (for poor housing, education, income), Charlson Comorbidity Index (CCI), and severe COVID-19 disease.

Results

Odds ratios (OR) of COVID-19 positivity for the combined UCLA + PSJH population, as well as OR of having severe COVID-19 disease in the UCLA cohort are presented (Table). OR[95%CI] for AKI were higher for ages ≥80 years (1.77[1.14-2.46]), ADI by state (1.12[1.06-1.18]), CKD (12.20[8.46-17.58]) and pre-existing DM (3.65[2.62-5.08]), p<0.001. In the UCLA CURE-CKD population, AKI was associated with severe COVID-19 (r=0.26) and ICU admissions (r=0.29). Mortality was associated with severe COVID-19 disease (r=0.5).

Conclusion

Non-White and/or LatinX race/ethnicity, ADI, CKD, DM, and older age were associated with higher risks of COVID-19 positivity, disease severity, and mortality in CURE-CKD. Efforts on viral screening, timely COVID-19 diagnosis, and optimal care delivery for patients with or at-risk for CKD are needed.

Funding

  • Private Foundation Support